Charles Darkoh1,2, Kadiatou Keita3, Chioma Odo2, Micah Oyaro4, Eric L Brown1, Cesar A Arias1,2,5, Blake M Hanson1,5, Herbert L DuPont1,2,6. 1. University of Texas Health Science Center, School of Public Health, Department of Epidemiology, Human Genetics, and Environmental Sciences, Center for Infectious Diseases, Houston, Texas,USA. 2. University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Microbiology and Infectious Diseases Program, Houston, Texas,USA. 3. Alabama A&M University, Huntsville, Alabama, USA. 4. University of Nairobi, School of Medicine, College of Health Sciences, Nairobi, Kenya. 5. Division of Infectious Diseases and Center for Antimicrobial Resistance and Microbial Genomics, UTHealth, McGovern School of Medicine at Houston, Houston, Texas, USA. 6. Kelsey Research Foundation, Houston, Texas, USA.
Abstract
BACKGROUND: Clostridioides difficile infection (CDI) is a leading cause of hospital-associated antibiotic-related diarrhea and deaths worldwide. Vancomycin is one of the few antibiotics recommended for both nonsevere and severe CDI cases. We sought to determine whether vancomycin nonsusceptible C. difficile strains are circulating in the patient population. METHODS: Stool samples from patients with CDI were collected from 438 and 98 patients at a large university hospital in Houston, Texas, and Nairobi, Kenya, respectively. The stools were examined for the presence of vancomycin and metronidazole nonsusceptible C. difficile using broth dilution culture, Etest (BioMérieux, France), polymerase chain reaction (PCR), whole-genome sequencing, and in vivo testing in a CDI mouse model. RESULTS: Of the Houston stool samples, 114/438 (26%) had vancomycin nonsusceptible C. difficile isolates and 128/438 (29%) were metronidazole nonsusceptible. Similarly, 66 out of 98 (67%) and 83/98 (85%) of the Nairobi patients harbored vancomycin and metronidazole nonsusceptible isolates, respectively. Vancomycin treatment of a CDI mouse model infected with a vancomycin nonsusceptible isolate failed to eradicate the infection. Whole-genome sequencing analyses did not identify vanA genes, suggesting a different mechanism of resistance. CONCLUSIONS: C. difficile strains exhibiting reduced susceptibility to vancomycin are currently circulating in patient populations. The spread of strains resistance to vancomycin, a first-line antibiotic for CDI, poses a serious therapeutic challenge. Routine susceptibility testing may be necessary.
BACKGROUND: Clostridioides difficile infection (CDI) is a leading cause of hospital-associated antibiotic-related diarrhea and deaths worldwide. Vancomycin is one of the few antibiotics recommended for both nonsevere and severe CDI cases. We sought to determine whether vancomycin nonsusceptible C. difficile strains are circulating in the patient population. METHODS: Stool samples from patients with CDI were collected from 438 and 98 patients at a large university hospital in Houston, Texas, and Nairobi, Kenya, respectively. The stools were examined for the presence of vancomycin and metronidazole nonsusceptible C. difficile using broth dilution culture, Etest (BioMérieux, France), polymerase chain reaction (PCR), whole-genome sequencing, and in vivo testing in a CDI mouse model. RESULTS: Of the Houston stool samples, 114/438 (26%) had vancomycin nonsusceptible C. difficile isolates and 128/438 (29%) were metronidazole nonsusceptible. Similarly, 66 out of 98 (67%) and 83/98 (85%) of the Nairobi patients harbored vancomycin and metronidazole nonsusceptible isolates, respectively. Vancomycin treatment of a CDI mouse model infected with a vancomycin nonsusceptible isolate failed to eradicate the infection. Whole-genome sequencing analyses did not identify vanA genes, suggesting a different mechanism of resistance. CONCLUSIONS: C. difficile strains exhibiting reduced susceptibility to vancomycin are currently circulating in patient populations. The spread of strains resistance to vancomycin, a first-line antibiotic for CDI, poses a serious therapeutic challenge. Routine susceptibility testing may be necessary.
Authors: David A Boyd; Tim Du; Romeo Hizon; Brynn Kaplen; Travis Murphy; Shaun Tyler; Shirley Brown; Frances Jamieson; Karl Weiss; Michael R Mulvey Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191
Authors: J Freeman; J Vernon; K Morris; S Nicholson; S Todhunter; C Longshaw; M H Wilcox Journal: Clin Microbiol Infect Date: 2014-10-13 Impact factor: 8.067
Authors: G P Young; P B Ward; N Bayley; D Gordon; G Higgins; J A Trapani; M I McDonald; J Labrooy; R Hecker Journal: Gastroenterology Date: 1985-11 Impact factor: 22.682
Authors: F Meyer; D Paarmann; M D'Souza; R Olson; E M Glass; M Kubal; T Paczian; A Rodriguez; R Stevens; A Wilke; J Wilkening; R A Edwards Journal: BMC Bioinformatics Date: 2008-09-19 Impact factor: 3.169
Authors: Deiziane V S Costa; Natalie V S Pham; Rachel A Hays; David T Bolick; Sophia M Goldbeck; Melinda D Poulter; Sook C Hoang; Jae H Shin; Martin Wu; Cirle A Warren Journal: Antimicrob Agents Chemother Date: 2022-07-21 Impact factor: 5.938